These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 15956187)
1. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Zhang H; Zhang A; Kohan DE; Nelson RD; Gonzalez FJ; Yang T Proc Natl Acad Sci U S A; 2005 Jun; 102(26):9406-11. PubMed ID: 15956187 [TBL] [Abstract][Full Text] [Related]
2. PPARγ agonist-induced fluid retention depends on αENaC expression in connecting tubules. Fu Y; Gerasimova M; Batz F; Kuczkowski A; Alam Y; Sanders PW; Ronzaud C; Hummler E; Vallon V Nephron; 2015; 129(1):68-74. PubMed ID: 25531136 [TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-γ agonists repress epithelial sodium channel expression in the kidney. Borsting E; Cheng VP; Glass CK; Vallon V; Cunard R Am J Physiol Renal Physiol; 2012 Mar; 302(5):F540-51. PubMed ID: 22169011 [TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. Song J; Knepper MA; Hu X; Verbalis JG; Ecelbarger CA J Pharmacol Exp Ther; 2004 Feb; 308(2):426-33. PubMed ID: 14593089 [TBL] [Abstract][Full Text] [Related]
5. Increased susceptibility of db/db mice to rosiglitazone-induced plasma volume expansion: role of dysregulation of renal water transporters. Zhou L; Liu G; Jia Z; Yang KT; Sun Y; Kakizoe Y; Liu M; Zhou S; Chen R; Yang B; Yang T Am J Physiol Renal Physiol; 2013 Nov; 305(10):F1491-7. PubMed ID: 24005472 [TBL] [Abstract][Full Text] [Related]
6. PPARγ-induced stimulation of amiloride-sensitive sodium current in renal collecting duct principal cells is serum and insulin dependent. Chraïbi A; Renauld S Cell Physiol Biochem; 2014; 33(3):581-93. PubMed ID: 24603133 [TBL] [Abstract][Full Text] [Related]
7. G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY. Wang S; Awad KS; Elinoff JM; Dougherty EJ; Ferreyra GA; Wang JY; Cai R; Sun J; Ptasinska A; Danner RL J Biol Chem; 2015 Aug; 290(32):19544-57. PubMed ID: 26105050 [TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Guan Y; Hao C; Cha DR; Rao R; Lu W; Kohan DE; Magnuson MA; Redha R; Zhang Y; Breyer MD Nat Med; 2005 Aug; 11(8):861-6. PubMed ID: 16007095 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs. Schinner S; Krätzner R; Baun D; Dickel C; Blume R; Oetjen E Br J Pharmacol; 2009 Jul; 157(5):736-45. PubMed ID: 19338578 [TBL] [Abstract][Full Text] [Related]
12. Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Lu M; Sarruf DA; Talukdar S; Sharma S; Li P; Bandyopadhyay G; Nalbandian S; Fan W; Gayen JR; Mahata SK; Webster NJ; Schwartz MW; Olefsky JM Nat Med; 2011 May; 17(5):618-22. PubMed ID: 21532596 [TBL] [Abstract][Full Text] [Related]
19. An insulin-sensitizing thiazolidinedione, which minimally activates PPARγ, does not cause bone loss. Fukunaga T; Zou W; Rohatgi N; Colca JR; Teitelbaum SL J Bone Miner Res; 2015 Mar; 30(3):481-8. PubMed ID: 25257948 [TBL] [Abstract][Full Text] [Related]
20. N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo. Bhalla K; Hwang BJ; Choi JH; Dewi R; Ou L; Mclenithan J; Twaddel W; Pozharski E; Stock J; Girnun GD J Biol Chem; 2011 Dec; 286(48):41626-41635. PubMed ID: 21979952 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]